What is Meril?
Founded in 2006, Meril operates as a comprehensive MedTech platform focused on the innovation, design, and development of novel medical devices. The company boasts a diversified product range spanning critical therapy areas including cardiovascular (with a focus on structural heart devices), orthopedics (encompassing implants and surgical robots), in-vitro diagnostics, and endo-surgery. Meril's commitment to robust research and development, coupled with world-class manufacturing capabilities, extensive distribution networks, and significant investment in education and training programs, has cemented its leading market status in India and facilitated its business operations in over 100 countries.
How much funding has Meril raised?
Meril has raised a total of $410M across 2 funding rounds:
Private Equity
$210M
Private Equity
$200M
Private Equity (2022): $210M with participation from Warburg Pincus
Private Equity (2025): $200M led by ADIA
Key Investors in Meril
ADIA
ADIA, established in 1976, manages a globally diversified investment portfolio across various asset classes. Headquartered in Abu Dhabi, United Arab Emirates, the firm is known for its strategic approach to long-term investment.
Warburg Pincus
Warburg Pincus LLC is a leading global private equity firm specializing in growth investing. The firm partners with investors and management teams to build sustainable success across diverse industries and market cycles.
What's next for Meril?
The recent major strategic investment signifies Meril's transition into a scaling phase, likely leveraging this capital to enhance its global footprint and accelerate the development of its innovative medical technologies. With a strong foundation in India and a presence in numerous international markets, Meril is well-positioned to capitalize on emerging opportunities in the MedTech sector. Future endeavors may include expanding its product pipeline, forging strategic partnerships, and further penetrating key global markets, building upon its established reputation for clinical relevance and state-of-the-art device development.
See full Meril company page
